Show
Sort by
-
Current practice in approaching controversial diagnostic and therapeutic topics in gastroenteropancreatic neuroendocrine neoplasm management : Belgian multidisciplinary expert discussion based on a modified Delphi method
-
Pooled analysis of the surgical treatment for colorectal cancer liver metastases
-
Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction : rationale for the Belgian way of working
-
Belgian guidelines for HER2 testing in gastric cancer
-
Familial adenomatous polyposis: clinical presentation, detection and surveillance
-
- Journal Article
- A1
- open access
Quality of care indicators in rectal cancer
-
EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients
-
Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical
-
Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicenter prospective phase II clinical study
-
Double blind randomized phase II study with radiation+5-fluorouracil +/- celecoxib for resectable rectal cancer
-
Three-year survival result of CORE (Capecitabine, Oxaliplatin, Radiotherapy and Excision) study after post-operative chemotherapy in patients with locally advanced rectal adenocarcinoma
(2009) -
Association of Progression-free Survival, Overall Survival, and Patient-reported Outcomes by Skin Toxicity and KRAS Status in Patients Receiving Panitumumab Monotherapy
-
DOUBLE BLIND RANDOMIZED PHASE II STUDY WITH RADIATION+5-FLUOROURACIL +/- CELECOXIB FOR RESECTABLE RECTAL CANCER
-
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
-
Quality assurance and recommendations for quality assessment of screening colonoscopy in Belgium.
-
Diagnostic pitfalls in digestive neuroendocrine tumours
-
Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?
-
The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
-
The potential role of targeted therapies in the management of neuroendocrine tumours
-
Locoregional and radioisotopic targeted treatment of neuroendocrine tumours
-
Carcinoid heart disease: a hidden complication of neuroendocrine tumours
-
The role of surgery and transplantation in neuroendocrine tumours
-
Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease.
-
A Phase IB/IIA, multicentre, randomised, double-blind placebo controlled study to evaluate the safety and pharmacokinetics of Z-360 in subjects with unresectable advanced pancreatic cancer in combination with gemcitabine
-
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refactory metastatic colorectal cancer (mCRC), treated wth irinotecan (q2w) and escalating dose of cetuximab (q1w): the EVEREST experience (preliminary data)
-
Adjuvant chemoradiation alone versus chemoradiation after curative resection for pancreatic cancer: feasibility results of a randomised EORTC/FFCD/GERCOR study (40013/22012/0304)
-
Association of KRAS mutational status and efficacy of panitumumab monotherapy for the treatment (tx) of metastatic colorectal cancer (mCRC): results of pooled data from 4 clinical studies.
-
DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease.
-
Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition.
-
The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab
-
Adjuvant chemoradiation after curative resection for pancreatic cancer is feasible: results of a randomised EORTC/FFCD/GERCOR study
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
-
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treted with cetuximab: a fluorescent in situ hybridization study
-
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hybridization study
-
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
-
Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan - A Belgian analysis
-
Vandetanib with Folfiri in patients with advanced colorectal adenocarcinoma: an open-label, multicenter phase I study
-
Efficacy and safety of panitumumab across five clinical studies in patients with metatastic colorectal cancer.
-
Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials
-
Safety of panitumumab, a fully huma monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients with metastatic colorectal cancer (mCRC) across clinical trial
-
A phase III randomized controlled trial of panitumumab in patients with metastatic colorectal cancer: subset analyses in elderly patients and in patients with poor performance status.
-
Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study.
-
Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST).
-
Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data
-
Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitumumab (Pmab)
-
Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts)
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
-
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
-
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
-
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
-
Capecitabine, Oxaliplatin, radiotherapy and excision (CORE) in patients with MIR-defined locally advanced rectal adenocarcinoma: results of an international multicenter phase II study
(2006) -
The value of patient-reported symptoms as prognostic factors for survival in advanced colorectal cancer
-
An international phase II study of Capecitabine, Oxaliplatin, Radiotherapy and Excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. Interim results.
-
Report on the Belgian consensus meeting on Colorectal cancer screening
-
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
-
Phase II study of irinotecan + 5FU/FA for patients with previously treated advanced gastric cancer
-
Raltitrexed plus Gemcitabine (TOMGEM) in advanced pancreatic cancer - Results of a Belgian Multicentre Phase II Study
-
Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839)
-
Raltitrexed/gemcitabine in patients with advanced biliary tract adenocarcinoma: a phase II study
-
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET)
-
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
-
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor).